NEW YORK (GenomeWeb News) – UK-based contract research and synthetic DNA firm SpheriTech said today that it has received an investment of an undisclosed sum from an anonymous angel investor.

The company is using the funds, which it said is in the six-figure range, to hire additional staff and to attract other investors and win government research grants or loans.

"For a company like ours to get off the ground, it's absolutely essential to secure government finance," SpheriTech CEO and Founder Don Wellings said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.